KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Debt (2016 - 2020)

Nektar Therapeutics has reported Non-Current Debt over the past 9 years, most recently at $254.8 million for Q1 2020.

  • Quarterly results put Non-Current Debt at $254.8 million for Q1 2020, up 3.0% from a year ago — trailing twelve months through Mar 2020 was $254.8 million (up 3.0% YoY), and the annual figure for FY2018 was $247.0 million, up 0.71%.
  • Non-Current Debt for Q1 2020 was $254.8 million at Nektar Therapeutics, up from $248.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for NKTR hit a ceiling of $254.8 million in Q1 2020 and a floor of $242.1 million in Q1 2016.
  • Median Non-Current Debt over the past 5 years was $245.4 million (2017), compared with a mean of $245.8 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 94.05% in 2016 and later rose 0.71% in 2019.
  • Nektar Therapeutics' Non-Current Debt stood at $243.5 million in 2016, then increased by 0.72% to $245.2 million in 2017, then increased by 0.71% to $247.0 million in 2018, then increased by 0.53% to $248.3 million in 2019, then grew by 2.64% to $254.8 million in 2020.
  • The last three reported values for Non-Current Debt were $254.8 million (Q1 2020), $248.3 million (Q3 2019), and $247.8 million (Q2 2019) per Business Quant data.